Detlef F. Albrecht
Chief Tech/Sci/R&D Officer chez SATSUMA PHARMACEUTICALS, INC.
Profil
Detlef F.
Albrecht was the founder of Relypsa, Inc. founded in 2007, where he held the title of Chief Medical Officer & SVP-Research & Development.
Currently, he is the Chief Medical Officer at Satsuma Pharmaceuticals, Inc. since 2017.
Dr. Albrecht's former positions include President, Chief Executive Officer & Director at Sorbent Therapeutics, Inc., Senior Director-Clinical Development at Miravant Medical Technologies, Director-Clinical Development at Schwarz Pharma, Inc., Vice President-Clinical Development at ALZA Corp., Chief Medical Officer & Senior Vice President at IntraBiotics Pharmaceuticals, Inc., Chief Medical Officer, SVP-Research & Development at Ilypsa, Inc., and Chief Medical Officer & Head-Drug Development at Armetheon, Inc. Dr. Albrecht holds a doctorate degree from RWTH Aachen University.
Postes actifs de Detlef F. Albrecht
| Sociétés | Poste | Début |
|---|---|---|
| SATSUMA PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01/07/2017 |
Anciens postes connus de Detlef F. Albrecht
| Sociétés | Poste | Fin |
|---|---|---|
Armetheon, Inc.
 Armetheon, Inc. Pharmaceuticals: MajorHealth Technology Armetheon, Inc. engages in medical development. It specializes in thrombosis and cardiac arrhythmias. The company was founded by Pascal J. Druzgala, Muralitharan Ken Kengatharan and Peter G. Milner in 2011 and is headquartered in Milpitas, CA. | Chief Tech/Sci/R&D Officer | 01/06/2017 |
Ilypsa, Inc.
 Ilypsa, Inc. BiotechnologyHealth Technology Ilypsa, Inc. operates a biopharmaceutical firm. It develops renal care pharmaceutical products. The company was founded on March 6, 2003 and is headquartered in Thousand Oaks, CA. | Chief Tech/Sci/R&D Officer | 02/01/2009 |
IntraBiotics Pharmaceuticals, Inc.
 IntraBiotics Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology IntraBiotics, a developer of antibiotics and antifungals is focused on one drug candidate, iseganan hydrochloride oral solution, which would be used for the prevention of ventilator-associated pneumonia and to help cystic fibrosis patients fight respiratory infections. | Chief Tech/Sci/R&D Officer | 22/01/2007 |
| ALZA CORPORATION | Corporate Officer/Principal | 01/01/2004 |
| MIRAVANT MEDICAL TECHNOLOGIES INC. | Corporate Officer/Principal | 01/01/1999 |
Formation de Detlef F. Albrecht
| RWTH Aachen University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| MIRAVANT MEDICAL TECHNOLOGIES INC. | Health Technology |
| Entreprise privées | 8 |
|---|---|
ALZA Corp.
 ALZA Corp. Pharmaceuticals: MajorHealth Technology ALZA Corp. provides drug delivery solutions and develops pharmaceutical products. The company applies its delivery technologies to develop pharmaceutical products with enhanced therapeutic value for its own portfolio and for many of the world's leading pharmaceutical companies. The company was founded by Martin Gerstel and Alejandro Zaffaroni in 1968 and is headquartered in Vacaville, CA. | Health Technology |
IntraBiotics Pharmaceuticals, Inc.
IntraBiotics Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology IntraBiotics, a developer of antibiotics and antifungals is focused on one drug candidate, iseganan hydrochloride oral solution, which would be used for the prevention of ventilator-associated pneumonia and to help cystic fibrosis patients fight respiratory infections. | Health Technology |
Sorbent Therapeutics, Inc.
 Sorbent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Sorbent Therapeutics, Inc. develops therapies for cardiovascular and renal diseases. It focuses on the development of non-absorbed polymeric drugs to satisfy unmet clinical needs in large cardiovascular and renal markets such as heart failure, chronic kidney disease and hypertension. The company was founded by William R. Rajski, Dean Abrassart, Donald W. Joseph and Lee W. Henderson on January 25, 2005 and is headquartered in Sunnyvale, CA. | Health Technology |
Ilypsa, Inc.
Ilypsa, Inc. BiotechnologyHealth Technology Ilypsa, Inc. operates a biopharmaceutical firm. It develops renal care pharmaceutical products. The company was founded on March 6, 2003 and is headquartered in Thousand Oaks, CA. | Health Technology |
Schwarz Pharma, Inc.
 Schwarz Pharma, Inc. Pharmaceuticals: MajorHealth Technology SCHWARZ PHARMA, Inc. develops and manufactures pharmaceutical products. The company's products include Codimal, Colyte, Edex, Kutrase, Levatol, Robaxin, and Verelan. It was founded in 2003 and is headquartered in Mequon, WI. | Health Technology |
Relypsa, Inc.
 Relypsa, Inc. Pharmaceuticals: MajorHealth Technology Relypsa, Inc. operates as a bio-pharmaceutical company, which engages in the development and commercialization of late-stage medicines in the iron deficiency, nephrology, and cardio-renal therapeutic areas. It offers Veltassa, a potassium binder approved for the treatment of hyperkalemia. The company was founded by Jerry M. Buysse, Gerrit Klaerner, Michael Burdick, Jay P. Shepard, Detlef F. Albrecht, George Tyson, Sandra I. Coufal and Vic Ciaravino on October 29, 2007 and is headquartered in Redwood City, CA. | Health Technology |
Armetheon, Inc.
Armetheon, Inc. Pharmaceuticals: MajorHealth Technology Armetheon, Inc. engages in medical development. It specializes in thrombosis and cardiac arrhythmias. The company was founded by Pascal J. Druzgala, Muralitharan Ken Kengatharan and Peter G. Milner in 2011 and is headquartered in Milpitas, CA. | Health Technology |
Satsuma Pharmaceuticals, Inc.
 Satsuma Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It develops novel therapeutic products for the acute treatment of migraines. Its product candidate, STS101, is a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, or DHE, which is designed to be self-administered with a proprietary pre-filled, single-use, nasal delivery device. The company was founded by John Kollins on June 21, 2016 and is headquartered in Durham, NC. | Health Technology |
